ELCC 2019 | PACIFIC trial updates: durvalumab after chemotherapy in NSCLC

Marina Garassino

Marina Garassino, MD, of National Cancer Institute of Milan, Milan, Italy, gives an update on the patient-reported outcomes from the Phase III PACIFIC study (NCT02125461), which investigated the efficacy of durvalumab in non-small cell lung cancer (NSCLC). Speaking at the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland, Dr Garassino concludes that the administration of durvalumab did not significantly impact the quality of life in NSCLC patients.

Share this video  
Similar topics